4 / 21
Page 38
Research & Reviews: Journal ofPharmaceutical Analysis | ISSN : 2320-0812
Euro Pharma Chemistry & Future Pharma 2019
June 27-28, 2019 | Amsterdam, Netherlands
12th World congress on
Joint Event
4
th
Pharmaceutical Chemistry Conference Future Pharma
Volume 08
Sarvesh Singh et al., Pharmaceutical Analysis 2019, Volume 08
Association of
NAT2
gene polymorphism with anti-tubercular drug
induced hepatotoxicity in North Indian population
Background:
Tuberculosis (TB) is one of the important causes of global mortality
and morbidity. Hepatotoxicity is a most serious adverse drug reaction of anti-TB
drugs. Various genetic factors are associated with drug-induced hepatotoxicity
(DIH). Anti-tubercular drugs are mostly metabolized by N-acetyltransferase
2
(NAT2)
. Therefore, in this study we aim to assess the association between of
NAT2
genotype polymorphism and drug-induced hepatotoxicity (DIH) in North
India population.
Methods:
TB patients were recruited in two groups. Seventy (70) TB patients
were enrolled as tolerant control group who did not develop DIH, whereas 30
TB patients in anti-tubercular DIH group who developed liver injury during
treatment. The genetic polymorphisms of the
NAT2
genes were analyses by PCR-
RFLP. Genotype and allele frequencies were evaluated by t-test and odds ratio
(OR) with 95% confidence intervals (CIs) to evaluate the strength of associations.
Results:
There is high percentage of slow acetylators among North Indian
population.The 4%people were fast acetylators, 34%were intermediate acetylators
and 62% were slow acetylators. Patients with the slow acetylator genotypes were
most common and there was no significant difference between DIH (73.33%) and
non-DIH (61.40%) patients. However, the slow-acetylator genotypes (
NAT2
*6/7,
NAT2
*5/7 and
NAT2
*5/6) were also not significantly different in anti-tubercular
DIH group and tolerant control group.
Conclusion:
In present study,
NAT2
genotype polymorphism was found to have
no association with development of anti- tubercular DIH
Biography
Sarvesh Singh has completed his MBBS from LLRM Medical College, Meerut, India and
MD from King George’s Medical University, Lucknow, India. He is an Associate Professor
in Pharmacology, Department at King George’s Medical University, Lucknow, India. He has
published more than 12 papers in reputed journals.
drsarveshsingh@gmail.comSarvesh Singh
King George’s Medical University
India
Co-Author
Divya Yadav, Anil Kumar Saksena,
Rahul Kumar, Preeti Mishra
and
Tanushree Kumar
King George’s Medical University, India